BHGI Summit 2018,

Seattle, Washington

Speakers:

• Ari Brooks, MD, Director of Endocrine and Oncologic Surgery and Director of the Integrated Breast Center at Pennsylvania Hospital
• Leah Eshraghi, MPH – Dr. Susan Love Research Foundation (USA)

First day of the BHGI Summit will focus on Phased Implementation for Breast Cancer Early Diagnosis. The didactic presentations and panel discussions will examine existing research and develop frameworks to guide phased implementation strategies for optimizing the time and accuracy of patient first presentation with breast signs and symptoms to the point of accurate diagnosis.

Day 1 Panel Co-Chairs:

Ophira Ginsburg, MD – NYU Langone’s Perlmutter Cancer Center (USA)

Cheng Har Yip, MD – University Malaya Medical Centre (Malaysia)

By 2025, 2.5 million women are expected to be diagnosed annually with breast cancer and 75% of breast cancer deaths will be in low-resource settings. Reducing this disparity and improving outcomes requires reducing barriers to early and accurate diagnosis and improving access to timely, appropriate care. Effective evidence-based resource-appropriate solutions are urgently needed to address the growing breast cancer burden disproportionately impacting women worldwide in low-resource settings.

Breast Health Global Initiative (BHGI) is a founding member of the Breast Cancer Initiative 2.5 (BCI2.5), a global campaign to reduce disparities in breast cancer outcomes for 2.5 million women by 2025. The activities and objectives of this Summit are intended to support global efforts to develop practical strategies to achieve this goal.

In collaboration with the National Comprehensive Cancer Network (NCCN), BHGI hosts this 3-day Global Summit on International Breast Health and Cancer Control: Improving Breast Health Care through Resource-Stratified Phased Implementation, which will bring together experts from a variety of resource settings. Over the course of the Summit, expert working groups will build on the innovative tools and guidelines developed by BHGI and NCCN to develop systematic, evidence-based implementation frameworks for translating resource-stratified guidelines into practice through a phased implementation approach.

iBreastExam (iBE), UELS’ flagship innovation, is a hand-held, radiation-free device operable by lay health workers with minimal training to provide clinically effective, limited-resource pre-screening for early diagnosis of breast cancer.

Over 150,000 women have received iBreastExam test in 12 countries. With promising results, iBE is clinically validated in USA, India, Brazil and Mexico in well over 10,000 women. With US FDA clearance, CE mark and other regulatory approvals, iBE is now commercially available and scaling in over 10 countries.

Using patented tactile sensor technology developed at Drexel University, for the first-time, women in the developing world have access to a safe, affordable, painless and standardized breast examination. The device is equally effective in younger women and women with dense breasts. iBE has won several coveted innovation awards and grants, including the Bayer and Pfizer Foundation grants, has been featured in the New York Times, BBC News and TED Talks.